Phase i study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer

Head and Neck

Volumn 34, Issue 11, 2012, Pages 1634-1639

  Nakamura, Tatsuya ^a   Fuwa, Nobukazu ^a   Takayama, Kanako ^a   Inokuchi, Haruo ^a   Tomoda, Takuya ^a   Takada, Akinori ^a   Makita, Chiyoko ^a   Shiomi, Miho ^a   Yokouchi, Jun Ichi ^a   Watanabe, Kazuo ^a  

^a Southern Tohoku General Hospital   (Japan)

Author keywords

arterial infusion; chemotherapy; cisplatin; docetaxel; head and neck cancer

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DERMATITIS; DISEASE COURSE; EVALUATION AND FOLLOW UP; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 84865323924     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21983     Document Type: Article

References (37)

1. Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK,. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 2000; 27 (4 Suppl 8): 25-33.
2. Lamont EB, Vokes EE,. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001; 2: 261-269.
3. Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999; 22: 1-5.
4. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK,. Head and neck cancer. N Engl J Med 1993; 328: 184-194.
5. Watson JC, Ridge JA,. Surgical management of local and regional recurrent head and neck squamous cell carcinoma. Curr Opin Oncol 1998; 10: 207-212.
6. Lee YY, Wallace S, Dimery I, Goepfert H,. Intraarterial chemotherapy of head and neck tumors. AJNR Am J Neuroradiol 1986; 7: 343-348.
7. Imai S, Kajihara Y, Munemori O, et al. Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers. Eur J Radiol 1995; 21: 94-99.
8. Korogi Y, Hirai T, Sakamoto Y, et al. Intravascular ultrasound imaging of peripheral arteries as an adjunct to atherectomy: preliminary experience. Br J Radiol 1995; 68: 110-115.
9. Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB,. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 1992; 14: 364-371.
10. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672-1678.
11. Forastiere AA, Shank D, Neuberg D, Taylor SGt, DeConti RC, Adams G,. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82: 2270-2274.
12. Schöffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10: 119-122.
13. Thödtmann F, Theiss F, Kemmerich M, et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1998; 9: 335-337.
14. Yabuuchi H, Kuroiwa T, Tajima T, Tomita K, Ochiai N, Kawamoto K,. Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone. Clin Oncol (R Coll Radiol) 2003; 15: 467-472.
15. Fuwa N, Ito Y, Matsumoto A, et al. A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer 2000; 89: 2099-2105.
16. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T,. A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 783-789.
17. Nakamura T, Kodaira T, Tachibana H, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol 2008; 38: 803-809.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
19. Gemmete JJ,. Complications associated with selective high-dose intraarterial cisplatin and concomitant radiation therapy for advanced head and neck cancer. J Vasc Interv Radiol 2003; 14: 743-748.
20. Balm AJ, Rasch CR, Schornagel JH, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26: 485-493.
21. Homma A, Furuta Y, Suzuki F, et al. Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer. Head Neck 2005; 27: 65-71.
22. Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 2005; 23: 1447-1454.
23. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T,. Treatment results of continuous intra-arterial CBDCA infusion chemotherapy in combination with radiation therapy for locally advanced tongue cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 714-719.
24. Fuwa N, Kodaira T, Furutani K, et al. Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases. Br J Cancer 2008; 98: 1039-1045.
25. Fuwa N, Kodaira T, Furutani K, et al. Arterial chemoradiotherapy for locally advanced tongue cancer: analysis of retrospective study of therapeutic results in 88 patients. Int J Radiat Oncol Biol Phys 2008; 72: 1090-1100.
26. Inohara H, Inoue T, Akahani S, et al. Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study. Anticancer Res 2004; 24: 4135-4140.
27. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK,. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12: 169-182.
28. Maeda S, Sugiura T, Saikawa Y, et al. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 2004; 95: 679-684.
29. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154-1161.
30. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20: 966-972.
31. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
32. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339-1348.
33. Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T,. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 2005; 35: 173-176.
34. Wahl MJ,. Osteoradionecrosis prevention myths. Int J Radiat Oncol Biol Phys 2006; 64: 661-669.
35. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010; 76: 1333-1338.
36. Ben-David MA, Diamante M, Radawski JD, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007; 68: 396-402.
37. Mitsudo K, Shigetomi T, Fujimoto Y, et al. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1428-1435.